Immunomodulating Properties of *Polygonum multiflorum* Extracts on Cyclophosphamide-induced Immunosuppression Model

H. J. YANG, M. J. KIM, H. J. KANG, H. Y. LEE¹, Y. M. PARK¹, Y. H. LEE¹, Y. G. KANG¹, G. P. HWA¹, Y. S. KANG², Y. M. JUNG³, N. K. LEE¹* AND K-H. PARK¹,⁵*

Korea Food Research Institute, 1201-62 Anyangpangyo-ro, Bundang-gu, Seungnam, Kyunggi 13539, ¹Invivo Co. Ltd., 460, Iksean-ro, Iksean, Jeonbuk 54538, ²Jiri mountain hasuo farming union corporation, 2605-63 Chinhwankyeong-ro, Geumseomyeon, Socheong, Gyeongnam, 52215, ³Department of Oriental Medicine Resources, Chonbuk National University, Iksean 54596, Korea, ⁴Department of Oriental Pharmaceutical Development, ⁵Department of Emergency Medical Rescue, Nambu University, Gwangju, 62271, Korea

Yang et al.: Immunostimulation by *Polygonum multiflorum* extracts

The objective of the present study was to investigate the immunomodulating property of *Polygonum multiflorum* extracts using various *in vitro* and *in vivo* tests. In this study, *Polygonum multiflorum* extracts were shown to exhibit immunomodulating activities such as cytokine production in normal rat splenocyte and cyclophosphamide-induced immunosuppression model. The immunostimulant effects of *Polygonum multiflorum* extracts were further tested for various immunological markers. *Polygonum multiflorum* extracts significantly enhanced cytokine production activity in rat splenocyte. Consistently oral administration of *Polygonum multiflorum* extracts enhanced blood cytokine production and ameliorated spleen damage in cyclophosphamide immunosuppressed rat. In conclusion, the present investigation revealed that *Polygonum multiflorum* extracts possessed immunomodulating and immunostimulating properties.

Key words: *Polygonum multiflorum* extracts, immunomodulation, immunostimulation, splenocytes, cyclophosphamide, emodin

*Polygonum multiflorum* is a traditionally highly efficient plant species that is cultivated in many countries and widely used as a source of Chinese medicine to treat various diseases like liver injury, cancer, diabetes, alopecia, atherosclerosis, neurodegenerative[¹], asthma, cerebral ischemia, steatosis, and Alzheimer’s disease[²-⁵]. Many studies showed that the major bioactive components of *P. multiflorum* are flavonoids and polyphenols including emodin, resveratrol, and 2,3,5,4'-tetrahydroxylstilbene-2-O-β-D-glucoside[⁶,⁷]. However, lesser is known about the enhancing immune response property of *P. multiflorum* extract (PME). Cancer and other infectious diseases treated by chemotherapies with immunosuppressive drugs

*Address for correspondence*  
E-mail: khpark@nambu.ac.kr

Accepted 29 May 2018  
Revised 26 October 2017  
Received 23 March 2017

such as cyclophosphamide lead to immunosuppressive response in patients\[^8\]. Cyclophosphamide is generally used to treat lymphocytic leukaemia, lymphoma, and specific solid tumours like bladder and ovarian cancer\[^9\]. However, treatment with cyclophosphamide often leads to serious side effects such as decrease in lineage of blood cells and its functional products including cytokines. Therefore, cyclophosphamide can be used as an immunosuppressive agent both in vitro and in vivo models\[^10,11\].

Immunomodulation-related cytokines such as interleukin-2 (IL-2), IL-12, tumor necrosis factor-α (TNF-α), Interferon gamma (IFN-γ), are well-identified targets used for amelioration of various immune diseases. Based on the evaluation of immunity, cyclophosphamide-induced immunomodulated mice exhibited significant immune-related differences compared to untreated mice, such as reduced activity of splenocytes, and repressed productions of TNF-α, IL-2 and IL-12 in serum and in splenocytes, suggesting that cyclophosphamide is a potent immunomodulators\[^12,13\]. Moreover spleen of normal and immunodeficient mice displayed significant changes in IFN-γ mRNA expression\[^14\]. Qi et al. reported that, cyclophosphamide treatment induced increase in spleen weight in mice\[^15\].

In this study, cultured primary splenocytes were used for the in vitro study, and cyclophosphamide-induced immunosuppressed rat was used for in vivo analysis. In order to assess the immunostimulating effects of PME the productions of various immunity-related cytokines such as IL-2, IL-12, TNF-α, IFN-γ in in vitro and in vivo models were investigated.

The whole plant of \(P.\) multiflorum was purchased from the Jiri Mountain \(P.\) multiflorum Co-operative Association in San Chung, G Jungnam Province, Korea. Dried tuberous root of \(P.\) multiflorum (1.0 kg) was extracted with 6.0 l of 70 % ethanol-DDW (v/v) at 80° for 3 h. The extracts were centrifuged at 3 000×g for 20 min at 4° and the supernatant was filtered through Whatman No. 3 filter paper and concentrated using a rotary evaporator. The supernatant extract was lyophilized to produce a sticky powder and then aliquots were kept at –80° until use to experiment. The yield of the ethanol extract of \(P.\) multiflorum was approximately 21.6 % of whole plants. The contents of total phenol and total flavonoids of extracts were 3205.11±40.32, 595.23±35.52 μg/g. Moreover, primary marker substance of \(P.\) multiflorum, emodin was analysed to 156.37±0.179 μg/g (fig. 1)\[^16\]. Microanalysis for liquid chromatography analysis of emodin contents in PME were measured using Agilent Technologies 1260 Infinity LC system (Agilent, Tokyo, Japan). Analysis was performed at the Mokpo Marine Food-Industry Research Center (Mokpo, Korea).

---

**Fig. 1: Chemical structure of emodin as marker molecule and profiling of contents in PME**

(A) Structure of emodin (6-methyl-1,3,8-trihydroxyanthraquinone, CAS# 518-82-1), (B) standard curve of emodin with 5, 10, 15, 20, 25, and 30 μg/ml (w/v) solution and (C) liquid chromatography profiles of standard molecule (upper panel, 150 ng, 10 μl as 15 μg/ml) and PME (lower panel, 100 μg, 10 μl as 10 mg/ml) in methanol
Male Sprague Dawley rats (SD; 6-8 w) purchased from Orient Bio (Sungnam, Korea) were acclimated for 7 d. All animals were housed in a controlled environment (22±3°C, 12-h light/dark cycle) during acclimation and the experiment and fed ad libitum with normal diet and water. All experiments approved by the Institutional Animal Care and Use Committee at Wonkwang University (Approval No. WKU16-20).

Splenocytes were obtained from SD rats. Briefly, the spleen was removed aseptically, washed thoroughly, diced and spleen cells were released by trituration. The splenocyte preparation was cleaned up by centrifugation and resuspending the pellet in Hank’s buffered salt solution (HBSS, pH 7.4), and the erythrocytes were lysed. The splenocyte preparation was again centrifuged, and splenocytes were washed two more times with HBSS. Cell count and viability were assessed by trypan blue exclusion prior to plating. Cells were resuspended in RPMI containing 10 % fetal bovine serum. Collected splenocytes were seeded on a 96-well plate with 100 μl of 2×10^5 cells/well. The final volume per well was 100 μl. Cells were incubated in a CO₂ incubator (5 % at 37°C) under humidified conditions for 24 h. A WST-1 assay kit (ITSBio, Seoul, Korea) or micro-culture tetrazolium assay (MTT) test [17,18] for splenocyte proliferation rate measurement and the results were determined using a Microplate-Reader (Molecular Devices, Sunnyvale, CA, USA).

Seven male rats per group were treated with saline or *P. multiflorum* oral administration once a day for 28 d, respectively. In every week, the rats are weighed, and their appearances were judged. After administration of samples, animals anesthetized with diethyl ether and whole blood was collected through the abdominal vena cava. Using the collected whole blood, each element of the blood cells, including neutrophils, eosinophils, basophils, and monocytes/macrophages, was measured with a Hemavet950 (Drew Scientific Group, Dallas, TX, USA).

To measure IL-2, IL-12, TNF-α and IFN-γ by ELISA, the splenocytes were stimulated with cyclophosphamide in 96-well plates according to Won *et al.* [19]. The supernatants harvested at 24 h and then transferred to 96-well ELISA plates. IL-2, IL-4, IL-10, IL-12, TNF-α and IFN-γ concentrations were determined using commercial ELISA kits (R&D system, Minneapolis, MN, USA).

All data are expressed as the mean±SEM. A one-way analysis of variance (ANOVA) test employed followed by Tukey’s multiple range tests to compare each group. Statistical analyses conducted using SPSS for Windows software (Ver 10.0, Chicago, IL, USA) and data with different superscript letters are significantly different when p value is less than 0.05.

The endogenous cytotoxicity of PME on rat splenocyte was evaluated through MTT assay. The multiple concentrations of PME were used and effective doses were calculated from dose-response results at 24 and 48 h. Results of the endogenous cytotoxicity evaluation against splenocytes of the PME are shown in fig. 2. The PME exhibited no significant activity against the splenocyte at ≤300 μg/ml. On the contrary, the high dose of PME exhibited significant cytotoxic effect against the splenocyte with ≥500 μg/ml at 24 and 48 h later. Therefore, optimal dosage of PME was 300 μg/ml was available for *in vitro* test with rat splenocytes and adjusted administrative dose for *in vivo* experiments.

Splenocytes of normal rats released cytokines when treated with various concentration (fig. 3). Low dose (<50 μg/ml) of PME did not induce release of TNF-α from splenocytes, whereas IFN-γ, IL-2, IL-12 release was increased compared to untreated group in a dose-dependent manner. TNF-α release was increased at a relative high dose (≥50 μg/ml) of PME in a dose-dependent manner from splenocytes compared to the untreated group.

To evaluate the immunopotentiating effect of PME *in vivo*, cyclophosphamide-induced immunosuppressed rats were administered with PME and the numbers
of peripheral leucocytes were measured (fig. 4). Treatment of cyclophosphamide significantly reduced the numbers of total white blood cells (WBC), lymphocytes absolute count (LYM), mid-range absolute count (MID), and neutrophil absolute count (NEUT) relative to the normal group after 4 w of cyclophosphamide treatment. Interestingly, a 4 w-treatment with PME reversed the numbers of

Fig. 3: Immunomodulating effects of PME on cytokine production in spleenocytes
Released (A) TNF-α, (B) IFN-γ, (C) IL-2, and (D) IL-12 were measured from culture supernatants at 48 h. ‘a’ and ‘b’ indicate significant difference at p<0.05. Data expressed as mean±SEM

Fig. 4: Effects of PME on leukocytes in cyclophosphamide-induced immunosuppressed rat model
Counts of (A) WBC (white blood cells), (B) LYM (lymphocytes), (C) MID (mid-range absolute count, monocyte+eosinophils+basophils), and NEUT (neutrophils) in whole blood were measured after 4 weeks. ‘a’, ‘b’ and ‘c’ indicate significant difference at p<0.05. Data expressed as mean±SEM
WBC, LYM, MID, and NEUT in cyclophosphamide-treated rats. Furthermore, PME-treated group showed normal body weight, consumption ratio of food and water as control group. Moreover, no severe symptoms such as death, bleeding, and diarrhoea were observed in all animals during these experiments.

Effect of PME on the expression of immunomodulating cytokines such as IL-2, IL-12, TNF-α and IFN-γ in cyclophosphamide-treated rats was assessed (fig. 5). As shown, treatment of cyclophosphamide significantly reduced the expression of IL-2, IL-12, TNF-α, and IFN-γ. However, PME treatment in cyclophosphamide-treated rat reversed these cytokines expressions than the normal rat in a dose-dependent manner. Cyclophosphamide-induced immunosuppression resulted in dramatically reduced spleen cellularity, both in white and red pulps compared to normal group (fig. 6). The white pulp became hardly identifiable with sparse areas. Only remnants of follicles and marginal zone indicated the original location of the white pulp. Abnormal aggregated cell populations, uneven distribution of haematopoesis, were observed in red pulp. Whereas, administration of PME ameliorated the disruption of splenic architecture in cyclophosphamide-induced rat model in a dose-dependent manner (fig. 6C-E). In PME-administrated group red pulp, white pulp, and marginal zone were almost re-established and recovered than control group.

Cyclophosphamide is generally used for immune suppressed model by typical cytotoxicity and increased the apoptotic cells in immune organ and tumor[9,20,21]. In this report, the cyclophosphamide-induced immunosuppression was verified by means of cytokines production both in vitro and in vivo. In other report, cyclophosphamide-induced immune modulation changes T and B lymphocyte subsets and increases cytokines release by Th1/Th2 lymphocytes in mice model[13]. After treatment with PME, rats had better body and organs weight compared to cyclophosphamide-treated group. Therefore, PME can protect spleen and other immune systems against cyclophosphamide-mediated immune impairment. However, cyclophosphamide treatment could release of many other cytokines and caspases, the intracellular death signal. In some report, cyclophosphamide treatment was reported to induce apoptosis-dependent[22], and/or apoptosis-independent[23] tumour regression in vivo and in vitro. However in this report, the focus was mainly on immunomodulation in animal model and positive effects were observed after the administration of PME. Furthermore this property of PME could be extended in other disease models for further studies.

Emodin, a well-known marker of P. multiflorum can also be isolated from many herbs such as Aloe vera, and Cassia obtusifolia[24]. Previous reports summarized various medicinal properties of emodin with antiviral, antibacterial, antiallergic, antiosteoporotic, antiabetic, immunosuppressive, neuroprotective

Fig. 5: Immunomodulating effects of PME on cytokine levels in cyclophosphamide-induced immunosuppressed rat model (A) TNF-α, (B) IFN-γ, (C) IL-2, and (D) IL-12 from serum were measured as described under materials and methods after 4 weeks. 'a' and 'b' indicate significant difference at p<0.05. Data expressed as mean±SEM.
and hepatoprotective activities\(^{[25]}\) with many mechanisms\(^{[26,27]}\). Although, it is possible for PME to have various components including carbohydrates, lipids, proteins, vitamins and minerals, therefore further studies are required. Finally, the data presented here showed that PME treatment could ameliorate immunosuppression and could be used as a therapeutic agent to treat such drug-induced problems.

**Acknowledgements:**

This work was supported by "Food Functionality Evaluation program" under the Ministry of Agriculture, Food and Rural Affairs and National Research Council of Science & Technology (NST) grant by the Korea government (MSIP; No. CAP-16-07-KIOM) and Korea Food Research Institute. K-H-P is recipient of research supporting grant of Nambu University (2017).

**Conflicts of interest:**

The authors declare that they have no competing interests.

**REFERENCES**


